Healthcare
Eton Pharmaceuticals, Inc.(ETON)
Live Price
Offline$32.48
-0.85% today
1Y Change
+138.15%
Window
Jun 25, 2025 โ Jun 15, 2026
- Market Cap
- $830.00M
- Revenue Growth
- +104.9%
- EPS Growth
- -13.3%
- Dividend Yield
- 0.0%
Coverage: 244 bars ยท Jun 25, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Eton Pharmaceuticals, Inc. (ETON) is a Healthcare stock with a market cap of $830.00M and listed on NASDAQ. The stock last traded around $32.48 and up 138.1% across the available one-year price window (Jun 25, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +104.9%, EPS growth of -13.3%, a dividend yield of 0.0%. What stands out right now is revenue +104.9%, EPS -13.3%, free cash flow +980.7% with operating margin -1.1% and ROIC -1.4%. Valuation already assumes a fairly strong business story at price/sales 10.4. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines ETON price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+104.9% vs +7.6% peer median
Operating Margin
Below sector median
-1.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +104.9% and EPS is at -13.3%, with operating margin around -1.1%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.9% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | +3.7% | +10.7% | +4.2% |
2026 Mar 19, 2026 | -58.3% | +7.5% | +12.9% | +20.6% |
2025 Nov 6, 2025 | -143.8% | -11.7% | -11.8% | -15.0% |
Benchmark Edge
ETON vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ETON
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ETON Max Drawdown
-36.17%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ETON and SPY.
Company Overview
Eton Pharmaceuticals, Inc.
NASDAQ Global Market
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
- Leadership
- Sean E. Brynjelsen
- IPO Date
- Nov 13, 2018
- Employees
- 31
- Street Address
- 21925 West Field Parkway
- Mailing
- Deer Park, IL, 60010-7208
- Region
- Deer Park, IL, US
- Reporting Currency
- USD
- Investor Line
- 847 787 7361
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 212.2
- Price/Sales
- 10.4
- Price/Book
- 31.3
Growth
- Revenue
- +104.9%
- EPS
- -13.3%
- Free Cash Flow
- +980.7%
Profitability
- Gross Margin
- 53.5%
- Operating Margin
- -1.1%
- Net Margin
- -5.8%
- ROE
- -18.8%
- ROIC
- -1.4%
Balance Sheet
- Debt/Equity
- 0.35
- Current Ratio
- 1.57
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.